JP7437847B2 - レレバクタムの誘導体およびその使用 - Google Patents

レレバクタムの誘導体およびその使用 Download PDF

Info

Publication number
JP7437847B2
JP7437847B2 JP2021517784A JP2021517784A JP7437847B2 JP 7437847 B2 JP7437847 B2 JP 7437847B2 JP 2021517784 A JP2021517784 A JP 2021517784A JP 2021517784 A JP2021517784 A JP 2021517784A JP 7437847 B2 JP7437847 B2 JP 7437847B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
formula
compound
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021517784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511392A5 (https=
JPWO2020072442A5 (https=
JP2022511392A (ja
Inventor
エム．ゴードン エリック
エイ．ジェイ．ダンクトン マシュー
フロイント ジョン
Original Assignee
アリクサ ファーマシューティカルズ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリクサ ファーマシューティカルズ、インコーポレイテッド filed Critical アリクサ ファーマシューティカルズ、インコーポレイテッド
Publication of JP2022511392A publication Critical patent/JP2022511392A/ja
Publication of JP2022511392A5 publication Critical patent/JP2022511392A5/ja
Publication of JPWO2020072442A5 publication Critical patent/JPWO2020072442A5/ja
Application granted granted Critical
Publication of JP7437847B2 publication Critical patent/JP7437847B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021517784A 2018-10-01 2019-10-01 レレバクタムの誘導体およびその使用 Active JP7437847B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739746P 2018-10-01 2018-10-01
US62/739,746 2018-10-01
PCT/US2019/053990 WO2020072442A1 (en) 2018-10-01 2019-10-01 Derivatives of relebactam and uses thereof

Publications (4)

Publication Number Publication Date
JP2022511392A JP2022511392A (ja) 2022-01-31
JP2022511392A5 JP2022511392A5 (https=) 2022-09-20
JPWO2020072442A5 JPWO2020072442A5 (https=) 2022-09-20
JP7437847B2 true JP7437847B2 (ja) 2024-02-26

Family

ID=68242885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517784A Active JP7437847B2 (ja) 2018-10-01 2019-10-01 レレバクタムの誘導体およびその使用

Country Status (6)

Country Link
US (1) US11180500B2 (https=)
EP (1) EP3860999B9 (https=)
JP (1) JP7437847B2 (https=)
CA (1) CA3114618C (https=)
ES (1) ES2991492T3 (https=)
WO (1) WO2020072442A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119431373B (zh) * 2024-07-24 2025-08-08 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510012A (ja) 2008-01-18 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658849A (en) 1969-02-19 1972-04-25 Reynolds Tobacco Co R Treatment of 2-substituted aldehydes with lead dioxide
DE3045373A1 (de) 1980-12-02 1982-07-01 Henkel KGaA, 4000 Düsseldorf Verwendung von estern der 3-hydrody-2,2-dimethylpropionsaeure als riechstoffe, diese enthaltende riechstoffkompositionen und 3-hydroxy-2,2-dimethyl-propionsaeurepropylester
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
TR200003199T2 (tr) * 1998-05-01 2001-03-21 Kyoto Pharmaceutical Industries, Ltd. Karbapenem türevleri, bunların kullanımı ve ara birleşiği
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002092606A1 (en) 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Fused imidazolidine derivatives, process for preparation of the same and use thereof
WO2009151392A1 (en) 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
EP2217564A1 (en) 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
GB0801401D0 (en) 2008-01-25 2008-03-05 Barry Callebaut Ag Composition
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
WO2010032147A2 (en) 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120053350A1 (en) * 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
CA2796750C (en) 2010-04-20 2017-09-19 Taisho Pharmaceutical Co., Ltd. Novel hydroxamic acid derivative
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
PL2657234T3 (pl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Optycznie czynna pochodna diazabicyklooktanowa i sposób jej wytwarzania
HUE027447T2 (en) 2011-05-30 2016-09-28 Sumitomo Chemical Co Cyclohexanone compounds and herbicides containing them
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
BR112017004796A2 (pt) 2014-09-12 2017-12-12 Toyama Chemical Co Ltd método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação
RU2017112319A (ru) 2014-09-12 2018-10-12 Тояма Кемикал Ко., Лтд. Новая фармацевтическая композиция, содержащая производное гидроксамовой кислоты или его соль
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
EP3281942A4 (en) 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
US20170165371A1 (en) 2017-02-22 2017-06-15 Joel Steven Goldberg Novel synthesis of potential ester prodrugs
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
EP3676247B8 (en) 2017-10-02 2023-04-12 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510012A (ja) 2008-01-18 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤

Also Published As

Publication number Publication date
EP3860999C0 (en) 2024-06-05
ES2991492T3 (es) 2024-12-03
EP3860999A1 (en) 2021-08-11
CA3114618C (en) 2023-09-05
US11180500B2 (en) 2021-11-23
WO2020072442A1 (en) 2020-04-09
JP2022511392A (ja) 2022-01-31
EP3860999B9 (en) 2024-08-14
CA3114618A1 (en) 2020-04-09
EP3860999B1 (en) 2024-06-05
US20200102307A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
AU2020227077B2 (en) Beta-lactamase inhibitors and uses thereof
EP3676247B1 (en) Aztreonam derivatives and uses thereof
US11008321B2 (en) Crystalline form of an avibactam derivative
JP7437847B2 (ja) レレバクタムの誘導体およびその使用
RU2815314C2 (ru) Ингибиторы бета-лактамаз и их применение
NZ758795B2 (en) Atropine pharmaceutical compositions
NZ758795A (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240206

R150 Certificate of patent or registration of utility model

Ref document number: 7437847

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150